Jupiter Neurosciences Marks Transformational First Year as a Public Company, Entering 2026 with Powerful Clinical and Commercial Momentum
Jupiter Neurosciences, Inc. (JUNS)
Company Research
Source: GlobeNewswire
Company advances JOTROL™ into Phase 2a Parkinson’s trial, launches Nugevia™ consumer brand, and strengthens financial position Jupiter, Florida, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced the publication of a shareholder letter from Chairman and CEO Christer Rosén marking Jupiter’s first full year as a public company and outlining the major achievements and strategic priorities propelling the Company into 2026. Dear Fellow Shareholders, As we celebrate our first full year as a public company, I want to express my deepest gratitude for your belief in Jupiter Neurosciences and the mission we are pursuing. When we completed our IPO in December 2024, we did more than enter the public markets — we stepped into a new era defined by bold ambition, scientific conviction, and the unwavering pursuit of improving h
Show less
Read more
Impact Snapshot
Event Time:
JUNS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JUNS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JUNS alerts
High impacting Jupiter Neurosciences, Inc. news events
Weekly update
A roundup of the hottest topics
JUNS
News
- Jupiter Neurosciences to Participate in NobleCon21 [Yahoo! Finance]Yahoo! Finance
- Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s DiseaseGlobeNewswire
- Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible FinancingGlobeNewswire
- Jupiter Neurosciences Names Visionary Entrepreneur and Biohacker Jean Fallacara as Third Nugevia™ Brand Ambassador [Yahoo! Finance]Yahoo! Finance
- Jupiter Neurosciences Names Visionary Entrepreneur and Biohacker Jean Fallacara as Third Nugevia™ Brand AmbassadorGlobeNewswire